SLC4A1 has clinical relevance as a biomarker for hereditary spherocytosis and as a therapeutic target in sickle cell disease and other red blood cell disorders [49].” CA1, is not broadly used as a biomarker. Here, SLC4A1 is linked to erythrocyte disorder.